U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.3Na.2H2O
Molecular Weight 294.0996
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRISODIUM CITRATE DIHYDRATE

SMILES

O.O.[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=NLJMYIDDQXHKNR-UHFFFAOYSA-K
InChI=1S/C6H8O7.3Na.2H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;2*1H2/q;3*+1;;/p-3

HIDE SMILES / InChI

Molecular Formula C6H7O7
Molecular Weight 191.1156
Charge -1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Doses

Doses

DosePopulationAdverse events​
540 mg 1 times / day multiple, oral
Recommended
Dose: 540 mg, 1 times / day
Route: oral
Route: multiple
Dose: 540 mg, 1 times / day
Co-administed with::
Thiamin oral 1.1 mg
Arginine oral 1240 mg
caffeine oral 52 mg
Sources: Page: p.2326
healthy, 24-59
n = 16
Health Status: healthy
Age Group: 24-59
Sex: M+F
Population Size: 16
Sources: Page: p.2326
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity.
1985 Oct
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.
1993
[Therapeutic use of potassium citrate].
2001
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:10 UTC 2023
Edited
by admin
on Fri Dec 15 15:32:10 UTC 2023
Record UNII
B22547B95K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRISODIUM CITRATE DIHYDRATE
II  
Systematic Name English
SODIUM CITRATE HYDRATE
JAN  
Systematic Name English
SODIUM CITRATE [FHFI]
Common Name English
Sodium citrate dihydrate [WHO-DD]
Common Name English
CITRIC ACID, TRISODIUM SALT, DIHYDRATE
Common Name English
SODIUM CITRATE DIHYDRATE [MI]
Common Name English
SODIUM CITRATE HYDROUS [II]
Common Name English
SODIUM CITRATE HYDRATE [JAN]
Common Name English
SODIUM CITRATE HYDROUS
II  
Common Name English
NATRII CITRAS, DEHYDRATE [WHO-IP LATIN]
Common Name English
SODIUM CITRATE, DIHYDRATE
WHO-IP  
Systematic Name English
SODIUM CITRATE, DIHYDRATE [WHO-IP]
Common Name English
N-1560
Code English
TRISODIUM CITRATE DIHYDRATE [II]
Common Name English
SODIUM CITRATE DIHYDRATE [VANDF]
Common Name English
FEMA NO. 3026
Code English
TRISODIUM CITRATE DIHYDRATE [USP MONOGRAPH]
Common Name English
SODIUM CITRATE DIHYDRATE
MI   VANDF   WHO-DD  
Systematic Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, TRISODIUM SALT, DIHYDRATE
Common Name English
SODIUM CITRATE [EP MONOGRAPH]
Common Name English
Code System Code Type Description
DRUG CENTRAL
4474
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
CAS
6132-04-3
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
MERCK INDEX
m10007
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C45678
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
CONCEPT Industrial Aid
RS_ITEM_NUM
1613859
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
CHEBI
32142
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
RXCUI
221163
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY RxNorm
PUBCHEM
71474
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
FDA UNII
B22547B95K
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TRISODIUM CITRATE DIHYDRATE
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Freely soluble in water and very soluble in boiling water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Systemic alkalinizing agent; component of oral rehydration salt mixtures. Storage: Sodium citrate should be kept in a tightly closed container. Labelling: The designation on the container of Sodium citrate should state whether the substance is the dihydrate or is in the anhydrous form. Additional information: Sodium citrate is slightly deliquescent in moist air. Definition: Sodium citrate contains not less than 99.0% and not more than 101.0% of C6H5Na3O7, calculated with reference to the anhydrous substance.
EVMPD
SUB51672
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID1049437
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
EVMPD
SUB16333MIG
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
NCI_THESAURUS
C66642
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
DRUG BANK
DB09159
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
DAILYMED
B22547B95K
Created by admin on Fri Dec 15 15:32:10 UTC 2023 , Edited by admin on Fri Dec 15 15:32:10 UTC 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY